论文部分内容阅读
目的 为了探讨乳腺癌病人nm23-Hl蛋白表达与临床预后的关系及意义.方法 采用免疫组化ABC法,对87例原发性乳腺癌手术标本经福尔马林固定、石蜡包埋组织进行nm23-H1蛋白表达的测定.结果乳腺癌原发灶中nm23-Hl表达阳性率为51.72%,区域淋巴结转移组阳性率为26%,无淋巴结转移组阳性率86.49%,差异具有显著性意义(P<0.001).随着乳腺癌核分裂的增多及病理学分级的增高,nm23-H1表达率下降.nm23-H1表达在生存期大于/等于5年及小于5年间及有无复发,脏器转移间差异显著(P<0.001).结论测定乳腺癌组织中nm23-H1表达,对判断转移和预后都有积极的临床意义.
Objective To investigate the relationship between the expression of nm23-Hl protein and clinical prognosis in patients with breast cancer. Methods Immunohistochemical ABC method was used to perform an immunohistochemical ABC method on 87 cases of primary breast cancer specimens fixed in formalin-fixed, paraffin-embedded tissues at nm23 The expression of H1 protein was detected. The positive rate of nm23-H1 expression was 51.72% in primary tumors of breast cancer, 26% in regional lymph node metastasis group and 86.49% in no lymph node metastasis group, and the difference was significant (P<0.05). <0.001). With the increase of breast mitosis and the increase of pathological grade, the expression rate of nm23-H1 decreased. The expression of nm23-H1 in the survival period is greater than/equal to 5 years and less than 5 years and there is no recurrence. The difference was significant (P<0.001). Conclusions The determination of nm23-H1 expression in breast cancer tissues has positive clinical significance for judging metastasis and prognosis.